Influence of chemotherapy courses on the rate of bloodstream infections during neutropenia in adult acute myeloid leukaemia

References

• Safdar N, Crnich CJ, Maki DG. Infectious complications of cancer therapy. Oncology, an evidence-based approach, AE Chang, PA Ganz, DF Hayes, TJ Kinsella, HI Pass, JH Schiller, RM Stone, VJ Strecher. Springer, New York 2006; 1363–400
   Google Scholar
• EOTRC International Antimicrobial Therapy Project Group. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. J Infect Dis 1978; 137: 14–29
   PubMedGoogle Scholar
• EORTC International Antimicrobial Therapy Cooperative Group. Geftazidime combined with a short or long course of amikacin for empirical therapy of Gram-negative bacteraemia in cancer patients with granulocytopenia. N Engl J Med 1987; 317: 1692–8
   PubMed Web of Science ®Google Scholar
• EORTC International Antimicrobial Therapy Cooperative Group. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119: 584–93
   PubMed Web of Science ®Google Scholar
• Bochud P-Y, Eggiman P, Calandra T, van Melle G, Saghafi L, Francioli P. Bacteraemia due to viridans Streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 1994; 18: 25–31
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Buzyn A, Leverger G, Herbrecht R, Hunault M, Leclercg R, et al. Epidemiology and risk factors for Gram-positive coccal infections in neutropenia: towards a more targeted antibiotic strategy. Clin Infect Dis 2003; 36: 149–58
   PubMed Web of Science ®Google Scholar
• Kinnunen U, Syrjälä H, Koskela M, Kujala P, Koistinen P. Continuous-monitoring blood culture screening system improves the detection of bacteraemia in neutropenic patients. Scand J Infect Dis 1996; 28: 287–92
   PubMed Web of Science ®Google Scholar
• Madani TA. Clinical infections and bloodstream isolates associated with fever in patients undergoing chemotherapy for acute myeloid leukaemia. Infection 2000; 28: 367–73
   PubMed Web of Science ®Google Scholar
• Elting LS, Rubenstein EB, Rolston KVI, Bodey GP. Outcomes of bacteraemia in patients with cancer and neutropenia: observations from 2 decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25: 247–59
   PubMed Web of Science ®Google Scholar
• Collin BA, Leather HL, Wingard JR, Ramphal R. Evolution, incidence and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis 2001; 33: 947–53
   PubMed Web of Science ®Google Scholar
• Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998; 16: 1179–87
   PubMed Web of Science ®Google Scholar
• Wolff SN, Herzig RH, Fay JW, Phillips GL, Lazarus HM, Flexner JM, et al. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukaemia in first remission. Long-term follow-up and results. J Clin Oncol 1989; 7: 1260–7
   PubMed Web of Science ®Google Scholar
• Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol 1992; 10: 1103–11
   PubMed Web of Science ®Google Scholar
• Peiris V, Oppenheimer BA. Antimicrobial activity of cytotoxic drugs may influence isolation of bacteria and fungi from blood cultures. J Clin Pathol 1993; 46: 1124–5
   PubMed Web of Science ®Google Scholar
• Kinnunen U, Koistinen P, Syrjälä H, Koskela M. Effects of anti-neoplastic agents on the recovery of bacteria and yeasts in an automated blood culture system. Scand J Infect Dis 2001; 32: 63–7
   Google Scholar
• Nyhlen A, Ljungberg B, Nilsson-Ehle I, Odenholt I. Bactericidal effect of combinations of antibiotic and antineoplastic agents against Staphylococcus aureus and Escherichia coli. Chemotherapy 2002; 48: 71–7
   PubMed Web of Science ®Google Scholar
• Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukaemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620–5
   PubMed Web of Science ®Google Scholar
• Ruutu T, Almqvist A, Hallman H, Honkanen T, Järvenpää E, Järventie G, et al. Oral induction and consolidation of acute myeloid leukaemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-d TAD. Finnish Leukaemia Group. Leukaemia 1994; 8: 11–5
   PubMed Web of Science ®Google Scholar
• Ruutu T, Hanninen A, Jarventie G, Koistinen P, Koivunen E, Kätkä K, et al. Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukaemia following MDS with idarubicin and cytarabine. Leuk Res 1997; 21: 133–8
   PubMed Web of Science ®Google Scholar
• Ruutu T, Koivunen E, Nousiainen T, Pelliniemi TT, Almqvist A, Anttila P, et al. Oral treatment of acute myeloid leukaemia with etoposide, thioguanine, and idarubicin (ETI) in elderly patients: a prospective randomized comparison with intravenous cytarabine, idarubicin, and thioguanine in the second and third treatment cycle. Eur J Haematol 2004; 72: 38–4
   PubMedGoogle Scholar
• Koistinen P, Räty R, Itälä M, Jantunen E, Koivunen E, Nousiainen T, et al. Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): the nationwide AML-92 study by the Finnish Leukaemia Group. Eur J Haematol 2007; 78: 477–85
   PubMed Web of Science ®Google Scholar
• Santolaya ME, Villarroel M, Avendano LF, Cofre J. Discontinuation of antimicrobial therapy for febrile, neutropenic children with cancer: a prospective study. Clin Infect Dis 1997; 25: 92–7
   PubMed Web of Science ®Google Scholar
• Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. APIC infection control and applied epidemiology: principles and practice, RN Olmsted. Mosby, St. Louis 1996; A1–20
   Google Scholar
• National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests – Approved Standard, 8th edn. NCCLS Document M2-A7, NCCLS, Villanova PAUSA, 2003].
   Google Scholar
• E-test technical manual, AB Biodisk, Solna, Sweden, 2000.
   Google Scholar
• Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805–12
   PubMed Web of Science ®Google Scholar
• Akova M, Paesmans M, Calandra T, Viscoli C for the International Antimicrobial Therapy Group of the European Organization for Research and Treatment of Cancer. A European organization for research and treatment of cancer: international antimicrobial therapy group study of secondary infections in febrile, neutropenic patients with cancer. Clin Infect Dis 2005;40:239–45.
   PubMed Web of Science ®Google Scholar
• Viscoli C, Varnier O, Machetti M. Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis 2005; 40(Suppl 4)S240–5
   PubMed Web of Science ®Google Scholar
• Costa SF, Miceli MH, Anaissie EJ. Mucosa or skin as source of coagulase-negative staphylococcalbacteraemia?. Lancet Infect Dis 2004; 4: 278–86
   PubMedGoogle Scholar
• Joel SP, Rohatiner A. Pharmacology of anti-leukaemic drugs 2002. Leukemia, ES Henderson, TA Lister, MF Greaves. Saunders, Philadelphia 2002; 394–440
   Google Scholar
• Bassan R. Management of infections in patients with leukemia. Leukemia, ES Henderson, TA Lister, MF Greaves. Saunders, Philadelphia 2002; 297–361
   Google Scholar
• Hooper DC, Wolfson JS. Mechanisms of quinolone action and bacterial killing. Quinolone antimicrobial agents, DC Hooper, JS Wolfson. American Society for Microbiology, Washington, DC 1993; 53–75
   Google Scholar
• Queen SA, Jagt DL, Reyes P. In vitro susceptibilities of Plasmodium falciparum to compounds, which inhibit nucleotide metabolism. Antimicrob Agents Chemother 1990; 34: 1393–8
   PubMed Web of Science ®Google Scholar